The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed the evidence in 2024 and concluded there is no causal link between GLP-1 receptor agonists and increased suicide risk, though continued monitoring is advised
Article 12 mins People Risks Are Rising: Heres How U.S
doi:10.2337/dc23-S011 Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbll T
Das Rohpeptid wird ausschlielich fr die wissenschaftliche Laborforschung (RUO) verkauft, nicht als fertiges Kosmetik- oder Medizinprodukt
Historical estimates used in the 2011 survey release have been updated following this same process
it represents the removal of the entire safety framework that legitimate programs provide